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Budd–Chiari syndrome secondary to lung cancer is very rare. The clinical features of this disease have not
been well described, as only a few cases have been reported in the past 3 decades. We analyzed 5 such
cases, including the present case, and have identiﬁed certain features of lung cancer that may play a role
in this syndrome. All cases had cancers originating in the right lung, and 4 cases were patients with non-
small cell lung cancers. Because of the rapid progression of liver failure, the prognosis for this syndrome
is very poor, and the effects of chemotherapy and/or radiotherapy are limited. Recently, however, new
treatments, such as stent placement therapy, have been shown to relieve pain and prolong life. We
describe a rare case of acute Budd–Chiari syndrome caused by tumor thrombus of the inferior vena cava
secondary to lung cancer. In addition, we discuss similar cases reported in the past 3 decades and the
effectiveness of stent placement therapy.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Budd–Chiari syndrome is caused by occlusion of the hepatic
vein or inferior vena cava and typically presents with the classical
triad of abdominal pain, ascites, and hepatomegaly. Direct
compression or invasion of vascular structures and the hyperco-
agulable state associated with malignancy can result in venous
thrombosis and obstruction. This syndrome can be fulminant,
acute, chronic, or asymptomatic, and is idiopathic in half of
patients. Only 10% of cases appear to result from compression of the
hepatic vein by an outside body like a tumor1; bronchogenic
carcinoma was cited as the cause of Budd–Chiari syndrome in only
a few cases.2–4
Here, we describe a rare case of acute Budd–Chiari syndrome
caused by tumor thrombus of the inferior vena cava secondary to
lung cancer. In addition, we review previous cases reported in the
past 3 decades and discuss the possibility of treatment with stent
placement therapy.2. Case report
An 83-year-old woman presented with an abnormality on
a chest radiograph. At the time of admission, physical examination
was normal. Laboratory evaluation conﬁrmed a normal blood count: þ81 75 751 4643.
ujita).and normal levels of liver enzymes, glucose, creatinine, and plasma
sodium and potassium. The patient had a history of chronic hepa-
titis C, for which she received no medication, and a 30 pack-year
history of smoking. Child-Pugh score on admission was class A.
Performance status (PS) of the patient was 1 on the Eastern
Cooperative Oncology Group (ECOG) scale.
An enhanced chest computed tomography (CT) scan in February
2008 showed a mass (3 3 cm) in the right upper lobe, swelling in
multiple mediastinal lymph nodes, and a left adrenal metastasis
(Fig. 1A). Specimens obtained by bronchoscope revealed poorly
differentiated non-small cell lung cancer (NSCLC). Gemcitabinewas
administered as single-agent chemotherapy, due to the patient’s
age and the presence of chronic hepatitis. She underwent 2 cycles
of chemotherapy, after which her cancer was classiﬁed as stable
disease.
In October 2008, she was presented for treatment again, this
timewith dyspnea, general fatigue, low-grade fever, and abdominal
discomfort. On admission, physical examination revealed mild
edema of the lower extremities. Her PS was 2 on the ECOG scale.
Laboratory data revealed slight elevation in lactate dehydrogenase
(LDH) at 298 IU/L and C-reactive protein (CRP) at 0.7 mg/dl. An
enhanced chest CT scan showed progression of the mass
(3.5 4 cm) in the right upper lobe. An enhanced abdominal CT
scan revealed mild splenomegaly, progressive adrenal gland
metastasis, and a tumor in the right atrium, inferior vena cava, and
hepatic vein, which suggests that a recurrence of NSCLC was
responsible for the onset of Budd–Chiari syndrome (Fig. 1, B-E).
Palliative care was provided to relieve pain and other distressing
Fig. 1. A) Chest CT scan shows a primary lung cancer of the right upper lobe in October 2008. (B, C) Enhanced abdominal CT scan shows a low-attenuation mass (arrows) in the liver
that has occupied and distended the vena cava (arrow). There is evidence of enhanced tumor vascularity (arrowheads) within the tumor. (D, E) A coronal section of the upper
abdomen and lower chest shows a tumor occupying the vena cava (arrows) and invading the right atrium (arrowheads).
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abdominal swelling, and progression of edema in the lower
extremities was observed. On the 14th day, laboratory data showed
that the aspartate aminotransferase (AST) level was 102 IU/L
(normal,<40), the alanine aminotransferase (ALT) level was 54 IU/L
(normal, <40), LDH level was 498 IU/L, total bilirubin (T-Bil) level
was 0.7 mg/dl, CRP level was 2.0 mg/dl, and prothrombin activity
was 80% of control. On the 16th day, a sudden decline in the level of
consciousness and aworsening of respiratory status were observed.
Emergency laboratory data showed that AST level was 863 IU/L
(normal,<40), ALT level was 267 IU/L (normal,<40), LDH level was
1258 IU/L, T-Bil level was 4.0 mg/dl, CRP level was 8.4 mg/dl,
prothrombin activity was 25% of control, and serum ammonia level
was 280 ug/dl. These data indicated the presence of acute liver
failure due to tumor thrombus of the inferior vena cava, i.e., Budd–
Chiari syndrome. She suffered respiratory failure and hypotension
on the 17th day, and died on the 18th day.
3. Discussion
The cause of Budd–Chiari syndrome cannot be determined in
half of patients. The most common known cause is coagulation
abnormality due to the concomitant presence of polycythemia
rubra vera and myeloproliferative disorders.3 Malignancies are
responsible for only approximately 10% of Budd–Chiari syndromeTable 1
Budd–Chiari syndrome secondary to lung cancer (MEDLINE search).
Reference Yeara Age Sexb Histology
Ough, et al.2 1981 60 M Squamous cell
Ough, et al.2 1981 66 M Squamous cell
Muretto, et al.3 1992 66 F Squamous cell
Demura, et al.4 1998 68 M Small cell
Present case 2008 83 F Non-small cell
a Year: year in press.
b Sex: M¼male, and F¼ female.
c Survival time: survival from the time of diagnosis.cases.1 Malignancies known to cause tumor thrombus are those of
the liver and kidney3,5; cancers of the lung, pancreas, and stomach
are only rarely implicated.1 Once rare, there has been a recent
increase in the number of the cases due to leiomyosarcoma.6–8
In our case, it appears that Budd–Chiari syndrome was caused by
direct invasion of the inferior vena cava by ametastasis to the adrenal
gland and ametastasis to the hepatic portal region. This is indicated by
the fact that ametastasis to the adrenal glandwas observed at the time
of ﬁrst diagnosis and had progressed at the time of the second evalu-
ation. CT ﬁndings provide additional support for this diagnosis.
We conducted a MEDLINE search to identify cases of Budd–Chiari
syndrome secondary to lung cancer that were reported in the past 3
decades; the characteristics of these, and our case, are summarized
in Table 1. There were 3 men and 2 women; all but our case were
diagnosed in their seventh decade. Histologically, 4 cases occurred in
patients with NSCLC, and 3 inpatients with conﬁrmed squamous cell
carcinoma. The primary tumors were located in the right lung in all
cases. Except for 1 casewith small cell lung cancer (SCLC), all patients
received best supportive care only and their outcomes were very
poor. In our case, salvage chemotherapy was not administered
because of her poor PS and her refusal to grant consent for therapy.
In general, patients with Budd–Chiari syndrome have already
suffered serious liver damage at the time of diagnosis. Although
chemotherapy is not usually indicated for NSCLC, it is an option in
the treatment of SCLC.4 Palliative radiotherapymay be beneﬁcial forLocation of primary cancer Treatment Survival timec
Right upper lobe None 2 Weeks
Right lower lobe None 4 Days
Right lower lobe None 6 Weeks
Right mediastinum Chemotherapy 6 Months
Right upper lobe None 4 Weeks
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patients with NSCLC. Recently, stent placement therapy has
received increasing attention. It was ﬁrst described by Charnsan-
gavej et al. in 19869 and since then, many patients have received
this treatment. It has been reported to be effective in a short period
of time; however, the only reports describing its effectiveness have
been small-scale retrospective studies.10,11 At this writing, there is
insufﬁcient evidence of its safety and efﬁcacy.
In conclusion, we described a rare case of Budd–Chiari
syndrome secondary to lung cancer and the clinical features of past
cases. Consideration of past cases suggests that there are certain
common features that are related to this syndrome. Although
Budd–Chiari syndrome secondary to lung cancer has a grim prog-
nosis, recent reports suggest that stent placement therapymight be
effective as a palliative therapy for this rare condition.
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